Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors

NCT04121286 is registered in ClinicalTrials.gov with Allist Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04121286
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04121286 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors
Lead sponsor
Allist Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 14, 2020
Completion date
June 17, 2022
Enrollment
17 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, non-small cell lung cancer, other solid tumors, pancreatic ductal carcinoma